Building upon its existing expertise in the diabetes space, Eli Lilly has agreed to acquire Sigilon Therapeutics for approximately US$34.6 M upfront, plus one non-tradeable contingent value right which could increase the deal value up to US$309.6 M. The companies have worked together since 2018 to develop Sigilon’s lead encapsulated cell therapy, SIG-002, for the treatment of type 1 diabetes (T1D). Interestingly, the deal comes one day after the US FDA approved the first cellular therapy for T1D, CellTrans’ Lantidra (donislecel).